Comparison of lixisenatide with sitagliptin and pioglitazone in non-alcoholic fatty liver diseases patients with type 2 diabetes after an acute coronary syndrome

Trial Profile

Comparison of lixisenatide with sitagliptin and pioglitazone in non-alcoholic fatty liver diseases patients with type 2 diabetes after an acute coronary syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Lixisenatide (Primary) ; Metformin; Pioglitazone; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 18 Oct 2016 New trial record
    • 16 Sep 2016 Results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top